NYSE:RMD - ResMed Stock Price, Price Target & More

Get Started

$102.85 +1.22 (+1.20 %)

(As of 05/21/2018 04:00 PM ET)

Previous Close$101.63

Today's Range$101.70 - $103.00

52-Week Range$68.41 - $104.78

Volume416,180 shs

Average Volume697,466 shs

Market Capitalization$14.51 billion

P/E Ratio36.48

Dividend Yield1.38%

Beta0.91

About ResMed (NYSE:RMD)

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides humidifiers, carry bags, and breathing circuits; and data communications and control products, such as EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators. It markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 120 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryHealth Care Equipment

SectorMedical

SymbolNYSE:RMD

CUSIP76115210

Webwww.resmed.com

Phone858-836-5000

Debt

Debt-to-Equity Ratio0.39

Current Ratio3.48

Quick Ratio2.85

Price-To-Earnings

Trailing P/E Ratio36.48

Forward P/E Ratio29.14

P/E GrowthN/A

Sales & Book Value

Annual Sales$2.07 billion

Price / Sales7.10

Cash Flow$3.6641 per share

Price / Cash28.07

Book Value$13.82 per share

Price / Book7.44

Profitability

EPS (Most Recent Fiscal Year)$2.82

Net Income$342.28 million

Net Margins13.52%

Return on Equity23.72%

Return on Assets13.66%

Miscellaneous

Employees6,080

Outstanding Shares142,740,000

ResMed (NYSE:RMD) Frequently Asked Questions

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Thursday, April 26th. Stockholders of record on Thursday, May 10th will be given a dividend of $0.35 per share on Thursday, June 14th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.36%. The ex-dividend date of this dividend is Wednesday, May 9th. View ResMed's Dividend History.

How were ResMed's earnings last quarter?

ResMed (NYSE:RMD) issued its quarterly earnings results on Thursday, April, 26th. The medical equipment provider reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.85 by $0.07. The medical equipment provider had revenue of $591.60 million for the quarter, compared to analysts' expectations of $575.75 million. ResMed had a net margin of 13.52% and a return on equity of 23.72%. ResMed's revenue was up 15.1% on a year-over-year basis. During the same quarter last year, the company posted $0.71 EPS. View ResMed's Earnings History.

When is ResMed's next earnings date?

ResMed is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for ResMed.

What price target have analysts set for RMD?

12 Wall Street analysts have issued 1-year price objectives for ResMed's stock. Their predictions range from $55.00 to $90.00. On average, they expect ResMed's share price to reach $68.80 in the next twelve months. View Analyst Ratings for ResMed.

What are Wall Street analysts saying about ResMed stock?

Here are some recent quotes from research analysts about ResMed stock:

1. According to Zacks Investment Research, "ResMed exited the third quarter on a promising note. The company achieved solid double-digit global revenue growth in the quarter, led by sales from Software-as-a-Service businesses as well as new mask products and devices. The company is also focusing on product innovation through research and development. In terms of recent developments, the company recently received reimbursement approval for mandibular repositioning devices in France. Further, the company announced that South Korea will start reimbursing diagnosis and therapeutic treatment for sleep apnea in the near term. All these factors boost investor faith in the stock. Over the past three months, ResMed has outperformed its industry. Yet, challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to challenging pricing scenario. Rising costs and a weak gross margin are other concerns." (5/1/2018)
2. Needham & Company LLC analysts commented, "We worked with Sleep Review magazine to survey US sleep centers. The survey included 136 responses received between 1/30/18 and 2/19/18. Compared to our prior (3Q17) survey, actual last-12-month patient volume growth decreased slightly while expected next-12-month patient volume growth increased slightly. RMD’s flow generator ratings were in line with Respironics’ ratings while RMD’s mask ratings were the highest but only slightly above its competitors’ ratings. RMD looks likely to gain branded flow generator prescription share but to lose branded mask prescription share. Overall, we think that the survey is mixed for RMD and we maintain our Hold rating." (3/7/2018)

Who are some of ResMed's key competitors?

Some companies that are related to ResMed include Fresenius (FSNUY), Boston Scientific (BSX), Baxter International (BAX), Abiomed (ABMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Penumbra (PEN), Cantel Medical (CMD), Insulet (PODD), Globus Medical (GMED), Haemonetics (HAE), Merit Medical Systems (MMSI) and NovoCure (NVCR).

Who are ResMed's key executives?

ResMed's management team includes the folowing people:

Mr. Michael J. Farrell BE, SM, MBA, Chief Exec. Officer and Director (Age 46)
Mr. Robert A. Douglas, Pres & COO (Age 58)
Mr. Brett A. Sandercock, Chief Financial Officer (Age 51)
Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 59)
Mr. James Hollingshead, Pres of Sleep Bus. (Age 55)

Has ResMed been receiving favorable news coverage?

Press coverage about RMD stock has trended somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ResMed earned a coverage optimism score of 0.09 on Accern's scale. They also assigned media stories about the medical equipment provider an impact score of 47.37 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are ResMed's major shareholders?

ResMed's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.84%), Baillie Gifford & Co. (3.41%), Northern Trust Corp (1.15%), JPMorgan Chase & Co. (0.68%), Millennium Management LLC (0.54%) and Legal & General Group Plc (0.52%). Company insiders that own ResMed stock include Brett Sandercock, Christopher G Roberts, David Pendarvis, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Mchale, Richard Sulpizio, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.

Which major investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including Bahl & Gaynor Inc., Guggenheim Capital LLC, Swiss National Bank, Baillie Gifford & Co., Northern Trust Corp, Copeland Capital Management LLC, Prudential Financial Inc. and Russell Investments Group Ltd.. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Peter C Farrell, Richard Mchale, Richard Sulpizio and Ronald R Taylor. View Insider Buying and Selling for ResMed.

Which major investors are buying ResMed stock?

RMD stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Rockefeller Capital Management L.P., Great Lakes Advisors LLC, Bellevue Group AG, State of Tennessee Treasury Department, BlackRock Inc. and Eaton Vance Management. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert, Ronald R Taylor and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $102.86.

How big of a company is ResMed?

ResMed has a market capitalization of $14.51 billion and generates $2.07 billion in revenue each year. The medical equipment provider earns $342.28 million in net income (profit) each year or $2.82 on an earnings per share basis. ResMed employs 6,080 workers across the globe.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]

MarketBeat Community Rating for ResMed (RMD)

Community Ranking:		1.6 out of 5 ()
Outperform Votes:		216 (Vote Outperform)
Underperform Votes:		465 (Vote Underperform)
Total Votes:		681

MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe RMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

ResMed (NYSE:RMD) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

12 Wall Street analysts have issued ratings and price targets for ResMed in the last 12 months. Their average twelve-month price target is $68.80, suggesting that the stock has a possible downside of 33.11%. The high price target for RMD is $90.00 and the low price target for RMD is $55.00. There are currently 3 sell ratings, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	1.92	1.91	2.00	1.91
Ratings Breakdown:	3 Sell Rating(s) 7 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	3 Sell Rating(s) 6 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	3 Sell Rating(s) 5 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	4 Sell Rating(s) 4 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$68.80	$68.80	$68.80	$64.50
Price Target Upside:	33.11% downside	31.69% downside	21.38% downside	23.60% downside

ResMed (NYSE:RMD) Consensus Price Target History

Price Target History for ResMed (NYSE:RMD)

ResMed (NYSE:RMD) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/24/2018	UBS	Downgrade	Buy ➝ Neutral		Medium
4/16/2018	William Blair	Reiterated Rating	Outperform		Low
4/4/2018	Citigroup	Downgrade	Buy ➝ Neutral		Medium
3/7/2018	Needham & Company LLC	Reiterated Rating	Hold		Medium
1/23/2018	Northland Securities	Upgrade	Under Perform ➝ Market Perform		High
1/23/2018	Macquarie	Downgrade	Neutral ➝ Sell		High
1/23/2018	BMO Capital Markets	Boost Price Target	Market Perform	$90.00	High
10/30/2017	JPMorgan Chase	Boost Price Target	Overweight	$72.00 ➝ $73.00	N/A
10/27/2017	Barclays	Boost Price Target	Underweight	$68.00 ➝ $70.00	N/A
10/12/2017	Jefferies Group	Reiterated Rating	Sell	$56.00	N/A
8/8/2017	Credit Suisse Group	Downgrade	Outperform ➝ Neutral		Low
8/2/2017	Bank of America	Downgrade	Buy ➝ Neutral		High
2/6/2017	Canaccord Genuity	Reiterated Rating	Hold	$59.00	N/A

(Data available from 5/21/2016 forward)

ResMed (NYSE:RMD) Earnings History and Estimates Chart

Earnings by Quarter for ResMed (NYSE:RMD)

ResMed (NYSE:RMD) Earnings Estimates

2018 EPS Consensus Estimate: $3.07
2019 EPS Consensus Estimate: $3.42

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$0.63	$0.65	$0.64
Q2 2018	2	$0.74	$0.77	$0.76
Q3 2018	2	$0.79	$0.79	$0.79
Q4 2018	2	$0.85	$0.92	$0.89
Q1 2019	2	$0.72	$0.76	$0.74
Q2 2019	2	$0.89	$0.91	$0.90
Q3 2019	2	$0.82	$0.91	$0.87
Q4 2019	2	$0.86	$0.96	$0.91

ResMed (NYSE RMD) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/30/2018		$0.94					N/A
4/26/2018	Q3 2018	$0.85	$0.92	$575.75 million	$591.60 million	View	N/A
1/22/2018	Q2 2018	$0.78	$1.00	$583.77 million	$601.27 million	View	Listen
10/26/2017	Q1 2018	$0.66	$0.66	$506.08 million	$523.66 million	View	N/A
8/1/2017	Q4 2017	$0.75	$0.77	$557.68 million	$556.69 million	View	Listen
4/27/2017	Q3 2017	$0.70	$0.71	$525.84 million	$514.20 million	View	N/A
1/23/2017	Q217	$0.70	$0.73	$518.60 million	$530.40 million	View	N/A
10/25/2016	Q117	$0.64	$0.62	$475.05 million	$465.45 million	View	Listen
7/28/2016	Q416	$0.74	$0.74	$512.37 million	$518.60 million	View	Listen
4/26/2016	Q316	$0.69	$0.68	$455.32 million	$453.90 million	View	Listen
1/21/2016	Q216	$0.66	$0.69	$445.46 million	$454.54 million	View	Listen
10/22/2015	Q116	$0.59	$0.58	$406.26 million	$411.70 million	View	Listen
7/30/2015	Q415	$0.65	$0.68	$436.27 million	$453.10 million	View	Listen
4/23/2015	Q315	$0.65	$0.65	$425.76 million	$422.50 million	View	Listen
1/22/2015	Q215	$0.62	$0.64	$408.20 million	$423.00 million	View	Listen
10/23/2014	Q115	$0.58	$0.58	$375.00 million	$380.40 million	View	Listen
7/31/2014	Q414	$0.66	$0.64	$433.42 million	$415.20 million	View	Listen
4/23/2014	Q314	$0.64	$0.63	$401.00 million	$397.80 million	View	Listen
1/23/2014	Q214	$0.63	$0.60	$398.09 million	$384.30 million	View	Listen
10/24/2013	Q114	$0.58	$0.56	$372.28 million	$357.66 million	View	Listen
8/1/2013	Q4 2013	$0.62	$0.62	$410.89 million	$414.60 million	View	Listen
4/25/2013	Q3 2013	$0.58	$0.58	$386.76 million	$383.60 million	View	Listen
1/24/2013	Q2 2013	$0.51	$0.53	$363.76 million	$376.50 million	View	Listen
10/25/2012		$0.46	$0.49			View	N/A
8/2/2012		$0.49	$0.53			View	N/A
4/26/2012		$0.41	$0.44			View	N/A
1/26/2012		$0.38	$0.42			View	N/A
10/24/2011		$0.35	$0.33			View	N/A
8/4/2011		$0.37	$0.37			View	N/A
4/28/2011		$0.35	$0.35			View	N/A
1/27/2011		$0.36	$0.37			View	N/A
10/28/2010	Q1 2011	$0.32	$0.36			View	N/A
8/5/2010	Q4 2010	$0.33	$0.34			View	N/A
4/29/2010	Q3 2010	$0.29	$0.32			View	N/A
2/4/2010	Q2 2010	$0.28	$0.31			View	N/A
11/5/2009	Q1 2010	$0.25	$0.29			View	N/A
8/6/2009	Q4 2009	$0.27	$0.31			View	N/A
5/7/2009	Q3 2009	$0.23	$0.25			View	N/A
2/5/2009	Q2 2009	$0.21	$0.22			View	N/A
11/6/2008	Q1 2009	$0.19	$0.18			View	N/A
8/5/2008	Q4 2008	$0.19	$0.19			View	N/A
5/1/2008	Q3 2008	$0.20	$0.19			View	N/A
2/7/2008	Q2 2008	$0.20	$0.18			View	N/A

(Earnings results data provided by Zacks Investment Research)

ResMed (NYSE:RMD) Dividend Information

ResMed pays an annual dividend of $1.40 per share, with a dividend yield of 1.36%. RMD's next quarterly dividend payment will be made on Thursday, June 14. The company has grown its dividend for the last 2 consecutive years and is increasing its dividend by an average of 8.70% each year. ResMed pays out 49.65% of its earnings out as a dividend.

Next Dividend:	6/14/2018
Annual Dividend:	$1.40
Dividend Yield:	1.36%
Dividend Growth:	8.70% (3 Year Average)
Payout Ratio(s):	49.65% (Trailing 12 Months of Earnings) 39.66% (Based on This Year's Estimates) 38.89% (Based on Next Year's Estimates) 38.21% (Based on Cash Flow)
Track Record:	2 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for ResMed (NYSE:RMD)

ResMed (NYSE:RMD) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/26/2018	quarterly	$0.35	1.44%	5/9/2018	5/10/2018	6/14/2018
1/22/2018	quarterly	$0.35	1.42%	2/7/2018	2/8/2018	3/15/2018
10/26/2017	quarterly	$0.35	1.66%	11/8/2017	11/9/2017	12/14/2017
8/2/2017	quarterly	$0.35	1.93%	8/15/2017	8/17/2017	9/21/2017
4/27/2017	quarterly	$0.33	1.94%	5/9/2017	5/11/2017	6/15/2017
1/23/2017	quarterly	$0.33	1.89%	2/7/2017	2/9/2017	3/16/2017
10/25/2016	quarterly	$0.33	2.18%	11/8/2016	11/10/2016	12/15/2016
7/28/2016	quarterly	$0.33	1.92%	8/16/2016	8/18/2016	9/22/2016
4/26/2016	quarterly	$0.30	2.12%	5/17/2016	5/19/2016	6/16/2016
1/21/2016	quarterly	$0.30	2.08%	2/9/2016	2/11/2016	3/17/2016
10/22/2015	quarterly	$0.30	2.13%	11/17/2015	11/19/2015	12/17/2015
7/30/2015	quarterly	$0.30	2.07%	8/18/2015	8/20/2015	9/17/2015
4/24/2015	quarterly	$0.28	1.7%	5/19/2015	5/21/2015	6/18/2015
1/23/2015	quarterly	$0.28	1.72%	2/10/2015	2/12/2015	3/19/2015
10/27/2014	quarterly	$0.28	2.17%	11/18/2014	11/20/2014	12/18/2014
8/1/2014	quarterly	$0.28	2.25%	8/19/2014	8/21/2014	9/18/2014
4/24/2014	quarterly	$0.25	2.11%	5/16/2014	5/20/2014	6/17/2014
1/24/2014	quarterly	$0.25	2.28%	2/14/2014	2/19/2014	3/19/2014
10/25/2013	quarterly	$0.25	2.02%	11/15/2013	11/19/2013	12/18/2013
8/2/2013	quarterly	$0.25	2.09%	8/16/2013	8/20/2013	9/17/2013
4/29/2013	quarterly	$0.17	1.44%	5/17/2013	5/21/2013	6/18/2013
1/25/2013	quarterly	$0.17	1.41%	2/14/2013	2/19/2013	3/19/2013

(Data available from 1/1/2013 forward)

ResMed (NYSE RMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.77%
Institutional Ownership Percentage: 62.27%

Insider Trading History for ResMed (NYSE:RMD)

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

ResMed (NYSE RMD) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/15/2018	Brett Sandercock	CFO	Sell	2,000	$101.52	$203,040.00	69,072
5/8/2018	Gary W Pace	Director	Sell	28,403	$97.37	$2,765,600.11	128,981
5/3/2018	David Pendarvis	Insider	Sell	2,810	$95.91	$269,507.10	98,043
5/1/2018	James Hollingshead	Insider	Sell	600	$94.69	$56,814.00	61,261
4/16/2018	Brett Sandercock	CFO	Sell	2,000	$99.36	$198,720.00	71,072
4/2/2018	James Hollingshead	Insider	Sell	600	$98.19	$58,914.00	59,940
3/15/2018	Brett Sandercock	CFO	Sell	2,000	$98.53	$197,060.00	73,072
3/5/2018	David Pendarvis	Insider	Sell	2,810	$94.08	$264,364.80	97,263
3/1/2018	James Hollingshead	Insider	Sell	600	$94.01	$56,406.00
2/15/2018	Brett Sandercock	CFO	Sell	2,000	$93.42	$186,840.00	75,072
2/5/2018	David Pendarvis	Insider	Sell	2,810	$96.03	$269,844.30	97,263
2/1/2018	Brett Sandercock	CFO	Sell	1,250	$100.13	$125,162.50	77,072
2/1/2018	Richard Mchale	Insider	Sell	2,000	$100.12	$200,240.00	62,002
1/26/2018	John P Wareham	Director	Sell	25,934	$102.25	$2,651,751.50	38,934
1/24/2018	Ronald R Taylor	Director	Sell	4,885	$99.71	$487,083.35	21,751
1/2/2018	Brett Sandercock	CFO	Sell	1,250	$84.99	$106,237.50	78,322
1/2/2018	James Hollingshead	Insider	Sell	600	$84.96	$50,976.00	62,602
12/4/2017	David Pendarvis	Insider	Sell	2,804	$84.17	$236,012.68	97,257
12/1/2017	Brett Sandercock	CFO	Sell	1,250	$85.36	$106,700.00	79,572
11/20/2017	James Hollingshead	Insider	Sell	7,019	$84.16	$590,719.04	66,409
11/9/2017	Peter C Farrell	Director	Sell	118,392	$82.70	$9,791,018.40	306,615
11/6/2017	Peter C Farrell	Director	Sell	20,000	$83.53	$1,670,600.00	314,800
11/3/2017	David Pendarvis	Insider	Sell	6,364	$82.20	$523,120.80
11/1/2017	Brett Sandercock	CFO	Sell	1,250	$84.50	$105,625.00	71,772
10/4/2017	Peter C Farrell	Director	Sell	20,000	$77.01	$1,540,200.00
10/3/2017	David Pendarvis	Insider	Sell	6,364	$76.94	$489,646.16
10/2/2017	Brett Sandercock	CFO	Sell	1,250	$77.05	$96,312.50	64,691
9/5/2017	David Pendarvis	Insider	Sell	6,364	$77.21	$491,364.44	93,172
9/5/2017	Peter C Farrell	Director	Sell	20,000	$76.74	$1,534,800.00	314,800
9/1/2017	Brett Sandercock	CFO	Sell	1,250	$77.56	$96,950.00	65,941
8/9/2017	Richard Sulpizio	Director	Sell	24,390	$73.85	$1,801,201.50	28,819
8/4/2017	Peter C Farrell	Director	Sell	20,000	$75.15	$1,503,000.00	321,557
8/3/2017	David Pendarvis	Insider	Sell	6,364	$72.10	$458,844.40	84,476
8/1/2017	Brett Sandercock	CFO	Sell	1,250	$77.49	$96,862.50	59,258
7/14/2017	James Hollingshead	Insider	Sell	7,140	$77.43	$552,850.20
7/5/2017	Peter C Farrell	Director	Sell	20,000	$76.50	$1,530,000.00	321,557
7/3/2017	Brett Sandercock	CFO	Sell	1,250	$77.44	$96,800.00	60,508
7/3/2017	David Pendarvis	Insider	Sell	6,364	$77.36	$492,319.04	84,476
6/29/2017	Jr. Gregor K Emmert	Insider	Buy	282,000	$0.07	$19,740.00
6/28/2017	Jr. Gregor K Emmert	Insider	Buy	424,000	$0.06	$25,440.00
6/22/2017	Richard Sulpizio	Director	Sell	65,887	$77.82	$5,127,326.34	4,429
6/15/2017	Gary W Pace	Director	Sell	24,390	$76.00	$1,853,640.00	99,317
6/5/2017	David Pendarvis	Insider	Sell	6,365	$72.62	$462,226.30	84,477
6/5/2017	Peter C Farrell	Director	Sell	20,000	$72.65	$1,453,000.00	321,557
6/1/2017	Brett Sandercock	CFO	Sell	1,250	$71.02	$88,775.00
5/4/2017	Peter C Farrell	Director	Sell	20,000	$68.75	$1,375,000.00	321,557
5/3/2017	David Pendarvis	Insider	Sell	6,365	$69.55	$442,685.75	84,261
5/1/2017	Brett Sandercock	CFO	Sell	1,250	$68.60	$85,750.00	62,783
4/17/2017	James Hollingshead	Insider	Sell	7,139	$68.37	$488,093.43	44,934
4/4/2017	Peter C Farrell	Director	Sell	20,000	$70.67	$1,413,400.00	321,557
4/3/2017	Brett Sandercock	CFO	Sell	1,250	$71.65	$89,562.50	64,033
4/3/2017	David Pendarvis	Insider	Sell	6,365	$71.59	$455,670.35	84,261
3/1/2017	Brett Sandercock	CFO	Sell	1,250	$72.48	$90,600.00	65,283
2/24/2017	John P Wareham	Director	Sell	28,403	$71.77	$2,038,483.31	41,403
2/20/2017	Christopher G Roberts	Director	Sell	10,000	$71.91	$719,100.00	145,610
2/15/2017	Franz Kozich	Director	Buy	50,000	$0.05	$2,500.00
2/14/2017	Warren Russell Hawkins	Director	Buy	60,000	$0.05	$3,000.00
2/6/2017	Peter C Farrell	Director	Sell	20,000	$68.32	$1,366,400.00	321,557
2/3/2017	David Pendarvis	Insider	Sell	6,365	$67.16	$427,473.40	84,261
1/17/2017	James Hollingshead	Insider	Sell	7,084	$64.44	$456,492.96	46,754
1/4/2017	Peter C Farrell	Director	Sell	20,000	$62.14	$1,242,800.00	321,557
1/3/2017	David Pendarvis	Insider	Sell	6,365	$61.95	$394,311.75	84,261
12/5/2016	David Pendarvis	Insider	Sell	6,365	$60.00	$381,900.00	84,261
12/5/2016	Peter C Farrell	Director	Sell	20,000	$59.83	$1,196,600.00	372,407
11/4/2016	Peter C Farrell	Director	Sell	20,000	$57.28	$1,145,600.00	367,978
11/3/2016	David Pendarvis	Insider	Sell	6,033	$57.79	$348,647.07
10/18/2016	James Hollingshead	Insider	Sell	1,967	$64.71	$127,284.57	45,513
10/17/2016	James Hollingshead	Insider	Sell	5,264	$64.43	$339,159.52	52,744
10/17/2016	Michael J Farrell	CEO	Sell	5,975	$64.25	$383,893.75	203,781
10/4/2016	Peter C Farrell	Director	Sell	20,000	$64.70	$1,294,000.00	364,063
10/3/2016	David Pendarvis	Insider	Sell	6,000	$63.95	$383,700.00	87,061
9/15/2016	Michael J. Farrell	CEO	Sell	5,975	$64.84	$387,419.00
9/6/2016	David Pendarvis	Insider	Sell	6,000	$67.18	$403,080.00	87,061
9/6/2016	Peter C Farrell	Director	Sell	20,000	$67.29	$1,345,800.00	367,978
8/19/2016	Gary W Pace	Director	Sell	36,000	$69.93	$2,517,480.00	129,158
8/17/2016	Ronald R Taylor	Director	Buy	2,487	$69.13	$171,926.31	16,729
8/16/2016	Ronald R Taylor	Director	Sell	23,102	$69.25	$1,599,813.50	16,729
8/15/2016	Michael J. Farrell	CEO	Sell	5,975	$70.41	$420,699.75
8/11/2016	Brett Sandercock	CFO	Sell	35,000	$70.50	$2,467,500.00
8/10/2016	Richard Sulpizio	Director	Sell	36,000	$70.15	$2,525,400.00	101,887
8/8/2016	John P Wareham	Director	Sell	24,390	$70.32	$1,715,104.80	37,390
8/4/2016	Peter C Farrell	Director	Sell	20,000	$69.16	$1,383,200.00	367,978
8/3/2016	David Pendarvis	Insider	Sell	6,000	$68.86	$413,160.00	80,512
7/15/2016	Michael J Farrell	CEO	Sell	5,975	$65.03	$388,554.25	154,814
7/14/2016	James Hollingshead	Insider	Sell	2,753	$65.02	$179,000.06	40,669
7/7/2016	Peter C Farrell	Director	Sell	20,000	$63.62	$1,272,400.00	367,978
7/5/2016	David Pendarvis	Insider	Sell	6,000	$63.62	$381,720.00	80,512
6/15/2016	James Hollingshead	Insider	Sell	4,458	$59.40	$264,805.20	43,422
6/15/2016	Michael J Farrell	CEO	Sell	5,975	$59.63	$356,289.25	154,814
6/6/2016	Peter C Farrell	Director	Sell	20,000	$59.82	$1,196,400.00	367,978
6/3/2016	David Pendarvis	Insider	Sell	6,000	$59.41	$356,460.00	80,512
5/16/2016	Michael J Farrell	CEO	Sell	5,975	$57.64	$344,399.00	154,723
5/4/2016	Peter C Farrell	Director	Sell	20,000	$55.90	$1,118,000.00	367,978
5/3/2016	David Pendarvis	Insider	Sell	6,000	$56.02	$336,120.00	80,287
4/15/2016	Michael J Farrell	CEO	Sell	5,975	$59.34	$354,556.50	154,723
4/4/2016	David Pendarvis	Insider	Sell	6,000	$58.70	$352,200.00	80,287
4/4/2016	Peter C Farrell	Director	Sell	20,000	$57.51	$1,150,200.00	367,978
3/15/2016	James Hollingshead	Insider	Sell	4,500	$58.57	$263,565.00	47,569
3/15/2016	Michael J Farrell	CEO	Sell	5,975	$58.57	$349,955.75	150,852
3/11/2016	Gary W Pace	Director	Sell	36,000	$60.00	$2,160,000.00	129,158
3/4/2016	Peter C Farrell	Director	Sell	20,000	$57.51	$1,150,200.00	367,978
3/3/2016	David Pendarvis	Insider	Sell	6,000	$57.26	$343,560.00	80,287
2/29/2016	Anne Reiser	Insider	Sell	1,946	$57.06	$111,038.76	76,300
2/26/2016	Brett Sandercock	CFO	Sell	30,000	$57.61	$1,728,300.00	132,136
2/26/2016	Richard Sulpizio	Director	Sell	36,000	$57.88	$2,083,680.00	101,887
2/25/2016	Peter C Farrell	Director	Sell	139,980	$57.31	$8,022,253.80	347,978
2/16/2016	Michael J. Farrell	CEO	Sell	5,975	$58.20	$347,745.00	144,878
2/4/2016	Peter C. Farrell	Director	Sell	20,000	$57.70	$1,154,000.00	347,978
2/3/2016	David Pendarvis	insider	Sell	6,000	$57.43	$344,580.00	74,287
1/27/2016	Franz Kozich	Director	Buy	60,000	$0.0350	$2,100.00
1/15/2016	Michael J. Farrell	CEO	Sell	5,975	$53.07	$317,093.25	144,878
1/4/2016	David Pendarvis	insider	Sell	6,000	$52.16	$312,960.00	74,287
1/4/2016	Peter C. Farrell	Director	Sell	20,000	$52.22	$1,044,400.00	347,978
1/4/2016	Robert Andrew Douglas	COO	Sell	6,337	$52.97	$335,670.89	31,304
12/15/2015	James Hollingshead	Insider	Sell	4,500	$55.95	$251,775.00	52,069
12/3/2015	David Pendarvis	insider	Sell	6,000	$59.38	$356,280.00	74,287
12/1/2015	Robert Andrew Douglas	COO	Sell	6,333	$59.77	$378,523.41	31,304
11/25/2015	Warren Russell Hawkins	Director	Buy	15,000	$0.0550	$825.00
11/24/2015	Warren Russell Hawkins	Director	Buy	3,000	$0.0550	$165.00
11/20/2015	Christopher G Roberts	Director	Sell	12,000	$59.03	$708,360.00	109,610
11/16/2015	Michael J. Farrell	CEO	Sell	5,975	$57.03	$340,754.25	144,878
11/12/2015	Donald Darkin	insider	Sell	25,442	$57.72	$1,468,512.24	13,684
11/2/2015	Robert Andrew Douglas	COO	Sell	6,333	$57.60	$364,780.80	68,391
10/27/2015	Anne Reiser	insider	Sell	3,000	$57.01	$171,030.00	83,214
10/15/2015	Michael J. Farrell	CEO	Sell	5,975	$55.35	$330,716.25	172,370
10/5/2015	David Pendarvis	insider	Sell	5,500	$52.47	$288,585.00	77,180
10/5/2015	Robert Andrew Douglas	COO	Sell	6,333	$52.13	$330,139.29	68,179
10/1/2015	Peter C. Farrell	Chairman	Sell	27,169	$50.93	$1,383,717.17	289,826
9/15/2015	James Hollingshead	Insider	Sell	4,455	$50.67	$225,734.85	67,680
9/15/2015	Michael J. Farrell	CEO	Sell	5,975	$50.89	$304,067.75	172,370
9/3/2015	David Pendarvis	insider	Sell	5,500	$51.78	$284,790.00	77,180
9/3/2015	Robert Andrew Douglas	COO	Sell	6,333	$52.04	$329,569.32	75,316
9/1/2015	Peter C. Farrell	Chairman	Sell	36,000	$50.82	$1,829,520.00	289,826
8/28/2015	Anne Reiser	insider	Sell	6,000	$52.26	$313,560.00	83,214
8/27/2015	Richard Sulpizio	Director	Sell	10,860	$51.83	$562,873.80	61,527
8/17/2015	Michael J Farrell	CEO	Sell	5,975	$55.54	$331,851.50
7/15/2015	Michael J Farrell	CEO	Sell	5,975	$57.59	$344,100.25
7/6/2015	David Pendarvis	Insider	Sell	5,500	$55.19	$303,545.00
7/1/2015	Peter C Farrell	Chairman	Sell	36,000	$55.61	$2,001,960.00
7/1/2015	Robert Andrew Douglas	COO	Sell	6,333	$56.59	$358,384.47
6/15/2015	Michael J Farrell	CEO	Sell	5,975	$57.87	$345,773.25
6/3/2015	David Pendarvis	Insider	Sell	5,500	$59.41	$326,755.00
6/1/2015	Peter C Farrell	Chairman	Sell	36,000	$59.25	$2,133,000.00
6/1/2015	Robert Andrew Douglas	COO	Sell	6,333	$59.22	$375,040.26
5/4/2015	David Pendarvis	Insider	Sell	5,500	$65.10	$358,050.00
4/6/2015	David Pendarvis	Insider	Sell	5,500	$72.60	$399,300.00
4/1/2015	Peter C Farrell	Chairman	Sell	36,000	$70.70	$2,545,200.00
4/1/2015	Robert Andrew Douglas	COO	Sell	6,333	$70.67	$447,553.11
3/27/2015	Warren Russell Hawkins	Director	Buy	10,000	$0.09	$900.00
3/26/2015	Warren Russell Hawkins	Director	Buy	10,000	$0.08	$800.00
3/16/2015	Anne Reiser	Insider	Sell	4,000	$69.10	$276,400.00
3/16/2015	Michael J Farrell	CEO	Sell	5,975	$69.10	$412,872.50
3/9/2015	Anne Reiser	Insider	Sell	3,000	$66.75	$200,250.00
3/2/2015	Peter C Farrell	Chairman	Sell	36,000	$64.64	$2,327,040.00
3/2/2015	Robert Andrew Douglas	COO	Sell	6,333	$64.39	$407,781.87
2/17/2015	Anne Reiser	Insider	Sell	5,000	$66.11	$330,550.00
2/5/2015	David Pendarvis	Insider	Sell	5,500	$62.35	$342,925.00
2/4/2015	John P Wareham	Director	Sell	36,000	$63.49	$2,285,640.00
2/3/2015	Brett Sandercock	CFO	Sell	18,670	$62.82	$1,172,849.40
2/3/2015	Robert Andrew Douglas	COO	Sell	6,333	$62.35	$394,862.55
2/2/2015	Peter C Farrell	Chairman	Sell	36,000	$61.97	$2,230,920.00
1/26/2015	Gary W Pace	Director	Sell	48,000	$66.77	$3,204,960.00
1/5/2015	David Pendarvis	Insider	Sell	5,500	$57.09	$313,995.00
1/2/2015	Peter C Farrell	Chairman	Sell	36,000	$56.99	$2,051,640.00
1/2/2015	Robert Andrew Douglas	COO	Sell	8,000	$56.99	$455,920.00
12/1/2014	Peter C Farrell	Chairman	Sell	36,000	$53.28	$1,918,080.00
12/1/2014	Robert Andrew Douglas	COO	Sell	8,000	$52.93	$423,440.00
11/18/2014	Peter C Farrell	Chairman	Sell	36,000	$52.39	$1,886,040.00
11/3/2014	David Pendarvis	Insider	Sell	3,557	$52.00	$184,964.00
11/3/2014	Robert Andrew Douglas	COO	Sell	8,000	$51.84	$414,720.00
10/29/2014	Peter C Farrell	Chairman	Sell	119,204	$51.84	$6,179,535.36
10/3/2014	David Pendarvis	Insider	Sell	5,000	$49.84	$249,200.00
10/1/2014	Robert Andrew Douglas	COO	Sell	8,000	$49.11	$392,880.00
9/15/2014	Michael J Farrell	CEO	Sell	3,200	$52.41	$167,712.00
9/5/2014	Brett Sandercock	CFO	Sell	10,000	$52.99	$529,900.00
9/3/2014	Brett Sandercock	CFO	Sell	10,000	$53.23	$532,300.00
9/3/2014	David Pendarvis	Insider	Sell	5,000	$53.23	$266,150.00
8/22/2014	Anne Reiser	Insider	Sell	3,000	$53.37	$160,110.00
8/4/2014	David Pendarvis	Insider	Sell	5,000	$49.12	$245,600.00
8/1/2014	Peter C Farrell	Director	Sell	25,000	$49.04	$1,226,000.00
8/1/2014	Robert Andrew Douglas	COO	Sell	8,000	$48.95	$391,600.00
7/15/2014	Michael J Farrell	CEO	Sell	3,200	$49.22	$157,504.00
7/3/2014	David Pendarvis	Insider	Sell	5,000	$50.04	$250,200.00
7/1/2014	Peter C Farrell	Director	Sell	25,000	$50.09	$1,252,250.00
7/1/2014	Robert Andrew Douglas	COO	Sell	8,000	$50.11	$400,880.00
6/16/2014	Michael J Farrell	CEO	Sell	3,200	$53.20	$170,240.00
6/3/2014	David Pendarvis	Insider	Sell	5,000	$49.76	$248,800.00
6/2/2014	Peter C Farrell	Director	Sell	25,000	$49.57	$1,239,250.00
6/2/2014	Robert Andrew Douglas	COO	Sell	8,000	$50.11	$400,880.00
5/29/2014	Christopher G Roberts	Director	Sell	25,000	$49.73	$1,243,250.00
5/15/2014	Michael Farrell	CEO	Sell	3,700	$50.54	$186,998.00	106,655
5/13/2014	John Wareham	Director	Sell	18,000	$51.00	$918,000.00	13,000
5/8/2014	Brett Sandercock	CFO	Sell	5,000	$50.00	$250,000.00	66,423
5/6/2014	Brett Sandercock	CFO	Sell	4,290	$50.00	$214,500.00	71,423
5/1/2014	Peter Farrell	Director	Sell	25,000	$49.80	$1,245,000.00	304,990
5/1/2014	Robert Andrew Douglas	COO	Sell	8,000	$49.75	$398,000.00
4/29/2014	David Pendarvis	Insider	Sell	15,000	$50.01	$750,150.00	68,956
4/21/2014	Peter Farrell	Director	Sell	75,000	$48.01	$3,600,750.00	304,990
4/4/2014	David Pendarvis	Insider	Sell	5,000	$44.95	$224,750.00	68,956
2/12/2014	Brett Sandercock	CFO	Sell	10,687	$46.00	$491,602.00	84,215
1/9/2014	Peter Farrell	Director	Sell	25,000	$48.00	$1,200,000.00	489,876
12/2/2013	Robert Andrew Douglas	COO	Sell	8,000	$49.10	$392,800.00	100,572
11/20/2013	Brett Sandercock	CFO	Sell	15,000	$51.06	$765,900.00	94,902
11/20/2013	James Hollingshead	Insider	Sell	4,000	$51.24	$204,960.00	26,285
11/12/2013	Donald Darkin	Insider	Sell	31,063	$50.04	$1,554,392.52	18,588
10/29/2013	David Pendarvis	Insider	Sell	37,744	$50.42	$1,903,052.48
10/1/2013	Peter C Farrell	Director	Sell	25,000	$53.21	$1,330,250.00
10/1/2013	Robert Andrew Douglas	COO	Sell	8,000	$53.20	$425,600.00
9/9/2013	Gary W Pace	Director	Sell	12,000	$50.05	$600,600.00
9/5/2013	Peter C Farrell	Director	Sell	25,000	$48.00	$1,200,000.00
9/3/2013	Robert Andrew Douglas	COO	Sell	8,000	$47.51	$380,080.00	123,892
8/28/2013	Michael Quinn	Director	Sell	48,000	$48.34	$2,320,320.00	880,000
8/27/2013	Brett Sandercock	CFO	Sell	5,000	$49.00	$245,000.00	109,012
8/26/2013	Christopher Roberts	Director	Sell	10,000	$49.49	$494,900.00	90,000
8/1/2013	Robert Andrew Douglas	COO	Sell	8,000	$48.57	$388,560.00
6/3/2013	Robert Andrew Douglas	COO	Sell	8,000	$47.96	$383,680.00
5/24/2013	Christopher G Roberts	Director	Sell	20,000	$49.45	$989,000.00
5/22/2013	John P Wareham	Director	Sell	18,000	$50.20	$903,600.00
5/13/2013	Michael A Quinn	Director	Sell	15,000	$50.94	$764,100.00
5/8/2013	Brett Sandercock	CFO	Sell	28,000	$48.97	$1,371,160.00
2/4/2013	Robert Andrew Douglas	COO	Sell	8,000	$44.14	$353,120.00
8/8/2012	Michael J Farrell	Insider	Sell	30,000	$35.58	$1,067,400.00

(Data available from 1/1/2013 forward)

ResMed (NYSE RMD) News Headlines

Source:

Date	Headline
	ResMed-sponsored Studies Show Combining Home Oxygen and Home Non-invasive Ventilation is a Cost Effective ... www.businesswire.com - May 20 at 5:27 PM
	ResMed-sponsored Studies Show Combining Home Oxygen and Home Non-invasive Ventilation is a Cost Effective Treatment for COPD finance.yahoo.com - May 20 at 5:27 PM
	ResMed (RMD) Receives Consensus Rating of "Hold" from Analysts www.americanbankingnews.com - May 20 at 3:33 PM
	Form 4 RESMED INC For: May 15 Filed by: Sandercock Brett www.streetinsider.com - May 17 at 9:00 AM
	Insider Selling: ResMed (RMD) CFO Sells 2,000 Shares of Stock www.americanbankingnews.com - May 16 at 10:29 PM
	Zacks: Brokerages Expect ResMed (RMD) Will Announce Quarterly Sales of $616.39 Million www.americanbankingnews.com - May 12 at 2:24 AM
	$0.92 EPS Expected for ResMed (RMD) This Quarter www.americanbankingnews.com - May 10 at 5:19 PM
	ResMed's New QuietAir Diffuser Vent for CPAP Masks Reduces Noise by 89 Percent www.businesswire.com - May 10 at 5:17 PM
	Form 4 RESMED INC For: May 08 Filed by: PACE GARY W www.streetinsider.com - May 10 at 5:17 PM
	Gary W. Pace Sells 28,403 Shares of ResMed (RMD) Stock www.americanbankingnews.com - May 10 at 7:31 AM
	ResMed Inc. (RMD) Ex-Dividend Date Scheduled for May 09, 2018 www.nasdaq.com - May 8 at 5:05 PM
	ResMed (RMD) Insider Sells $269,507.10 in Stock www.americanbankingnews.com - May 4 at 10:14 PM
	ResMed Inc. (RMD) Insider James Hollingshead Sells 600 Shares www.americanbankingnews.com - May 2 at 1:24 PM
	ResMed (RMD) Downgraded by Zacks Investment Research www.americanbankingnews.com - May 1 at 10:02 AM
	ResMed Inc. to Post FY2018 Earnings of $3.50 Per Share, William Blair Forecasts (RMD) www.americanbankingnews.com - April 30 at 3:40 AM
	Global Sleep Apnea Devices Market Forecasts to 2023 - A $6.5 Billion Market Opportunity with ResMed, Koninklijke ... www.businesswire.com - April 27 at 9:14 AM
	ResMed (RMD) Q3 2018 Results - Earnings Call Transcript seekingalpha.com - April 27 at 9:14 AM
	ResMed (RMD) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS www.americanbankingnews.com - April 26 at 8:10 PM
	ResMed Inc. (RMD) Plans Quarterly Dividend of $0.35 www.americanbankingnews.com - April 26 at 6:52 PM
	Resmed Q3 18 Earnings Conference Call At 4:30 PM ET www.nasdaq.com - April 26 at 4:55 PM
	ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2018 finance.yahoo.com - April 26 at 4:55 PM
	ResMed: Fiscal 3Q Earnings Snapshot finance.yahoo.com - April 26 at 4:55 PM
	ResMed Inc. (RMD) Given Average Recommendation of "Hold" by Brokerages www.americanbankingnews.com - April 25 at 5:30 PM
	ResMed Inc. (RMD) Expected to Post Quarterly Sales of $564.87 Million www.americanbankingnews.com - April 25 at 4:25 AM
	ResMed (RMD) Stock Rating Lowered by UBS www.americanbankingnews.com - April 24 at 9:29 AM
	UBS & Macquarie deliver ratings on ResMed Inc. ahead of profit report www.fool.com.au - April 24 at 8:48 AM
	Analysis: Positioning to Benefit within Korn/Ferry International, ResMed, Donaldson, Ollie's Bargain Outlet, VSE, and ... globenewswire.com - April 23 at 8:39 AM
	Medical Equipment Stocks' Research Reports Released on Myomo, Neovasc, ResMed, and Wright Medical www.prnewswire.com - April 23 at 8:39 AM
	Analysis: Positioning to Benefit within Korn/Ferry International, ResMed, Donaldson, Ollie's Bargain Outlet, VSE, and STARWOOD PROPERTY TRUST, INC — Research Highlights Growth, Revenue, and Consolidated Results finance.yahoo.com - April 23 at 8:39 AM
	Zacks: Brokerages Expect ResMed Inc. (RMD) to Announce $0.83 EPS www.americanbankingnews.com - April 23 at 7:16 AM
	BRIEF-Resmed Says Co Entered Certain Amended And Restated Credit Agreement, Dated As Of Closing Date www.reuters.com - April 20 at 8:58 AM
	3 reasons why I'm bullish on ResMed Inc. (CHESS) www.fool.com.au - April 20 at 8:58 AM
	ResMed (RMD) Set to Announce Quarterly Earnings on Thursday www.americanbankingnews.com - April 19 at 1:21 AM
	Form 4 RESMED INC For: Apr 16 Filed by: Sandercock Brett www.streetinsider.com - April 18 at 8:51 AM
	William Blair Reiterates Outperform Rating for ResMed (RMD) www.americanbankingnews.com - April 18 at 8:36 AM
	ResMed Inc. (RMD) CFO Brett Sandercock Sells 2,000 Shares www.americanbankingnews.com - April 17 at 10:33 PM
	ResMed (RMD) Lowered to "Buy" at BidaskClub www.americanbankingnews.com - April 16 at 5:24 PM
	Bank of America Lowers ResMed (RMD) to Neutral www.americanbankingnews.com - April 14 at 11:49 AM
	ResMed (RMD) Given "Sell" Rating at Needham & Company LLC www.americanbankingnews.com - April 14 at 10:35 AM
	ResMed (RMD) Downgraded to "Neutral" at Credit Suisse Group www.americanbankingnews.com - April 14 at 10:35 AM
	ResMed (RMD) Upgraded by Citigroup to "Buy" www.americanbankingnews.com - April 14 at 10:35 AM
	ResMed (RMD) PT Raised to $70.00 www.americanbankingnews.com - April 14 at 9:37 AM
	ResMed (RMD) versus Baxter International (BAX) Financial Analysis www.americanbankingnews.com - April 11 at 9:59 AM
	Australia and New Zealand at healthcare cutting edge www.ft.com - April 10 at 5:02 PM
	ResMed (RMD) Upgraded to Buy by Zacks Investment Research www.americanbankingnews.com - April 9 at 2:58 PM
	ResMed Inc. (RMD) Expected to Post Quarterly Sales of $562.33 Million www.americanbankingnews.com - April 8 at 3:58 AM
	ResMed Inc. (RMD) Expected to Post Earnings of $0.83 Per Share www.americanbankingnews.com - April 6 at 9:19 AM
	JPMorgan Chase Boosts ResMed (RMD) Price Target to $73.00 www.americanbankingnews.com - April 4 at 1:23 PM
	ResMed (RMD) Rating Lowered to Neutral at Citigroup www.americanbankingnews.com - April 4 at 12:49 PM
	Top broker slaps $175 price target on CSL Limited shares www.fool.com.au - April 4 at 8:53 AM

ResMed (NYSE:RMD) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

ResMed (NYSE:RMD) Income Statement, Balance Sheet and Cash Flow Statement

ResMed (NYSE RMD) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff